Treatment

xevinapant, Erbitux 5 mg/mL solution for infusion, xevinapant placebo clinical trials

1 indexed studies · 0 currently recruiting

Ongoing, recruitingTherapeutic confirmatory (Phase III)
A double-blind randomized, Phase III study of radiotherapy combined with cetuXimab + Xevinapant compared to radiotherapy combined with cetuximab (Standard of care) + placebo in patients with Locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN), unfit for high-dose cisplatin (XXL study)
This study compares a new drug, xevinapant, plus standard treatment for an advanced form of head and neck cancer. Researchers want to see if adding xevinapant helps patients live longer without their cancer getting worse, compared to the standard treatment alone.
For: Locally advanced squamous cell carcinoma of the head and neck
France